Zobrazeno 1 - 10
of 286
pro vyhledávání: '"A H, Boss"'
Autor:
Leah Shepherd, Neil Skolnik, Linong Ji, Terry Dex, Lawrence Blonde, Xuejun Victor Peng, Rory J. McCrimmon, Robert Lubwama, Angelo Avogaro, Anders H. Boss
Publikováno v:
Diabetes Therapy
Introduction Injectable therapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and basal insulin (BI) are well-established agents for people with type 2 diabetes (T2D). This study aimed to investigate real-world effectiveness of GLP-
Publikováno v:
Diabetes Therapy
Introduction Type 2 diabetes mellitus (T2DM) requires long-term treatment to achieve and maintain glycaemic control; however, up to 50% of people with T2DM discontinue treatment by 1 year. It is therefore important to understand the patient perspecti
Autor:
Vivian Fonseca, Agustina Alvarez, Rory J. Mccrimmon, Anders H. Boss, Alice Y. Cheng, Lydie Melas-Melt, Julio Rosenstock, Francesco Giorgino, Elisabeth Souhami, Philip Home
Publikováno v:
Diabetes. 70
Introduction: Therapeutic approaches to advancing treatment from basal insulin in T2D require assessment of the benefits and risks of any chosen intervention. Methods: SoliMix was a 26-week, open-label, multicenter study in which adults (N=887) with
Autor:
Elisabeth Souhami, Julio Rosenstock, Thamer Alessa, Alice Y. Cheng, Anders H. Boss, Agustina Alvarez, Ricardo Choza, Vivian Fonseca, Pascaline Picard, Rory J. McCrimmon
Publikováno v:
Diabetes. 70
Introduction: Advancing treatment from basal insulin (BI) to premix insulin may improve glycemic control, though at the expense of greater hypoglycemia risk, including nocturnal hypoglycemia. Methods: SoliMix was a 26-week open-label, multicenter, ra
Autor:
Robert Lubwama, Clare L. Gillies, Terry Dex, Muna Adan, Kamlesh Khunti, Francesco Zaccardi, Anders H. Boss, Samuel Seidu
Publikováno v:
Diabetes. 69
Using the Clinical Practice Research Datalink, adults diagnosed with T2DM newly initiated with a basal long/intermediate-acting insulin from January 2004 to December 2016 were identified. First change or add on of short or premix insulin and/or OADs
Publikováno v:
Diabetes. 69
T2D is a chronic condition that requires long-term treatment to achieve and maintain glycemic control. However, up to 50% of people with T2D discontinue treatment by 1 year. To better understand why this occurs, an online questionnaire was presented
Publikováno v:
Diabetes. 68
iGlarLixi, a fixed-ratio combination of insulin glargine U100 (iGlar-100) and the GLP-1 RA lixisenatide, has been available in the U.S. for clinical use in patients (pts) with T2D since 01/2017. This analysis provides baseline characteristics of iGla
Publikováno v:
In Experimental and Molecular Pathology 2004 77(2):145-148
Autor:
Lawrence Blonde, Xuejun Victor Peng, Alka Shaunik, Rory J. McCrimmon, Anders H. Boss, Kyu Rhee, Supriya Kumar, Sidhartha Balodi, Claire Brulle-Wohlhueter, Luigi F. Meneghini
Publikováno v:
Diabetes Therapy
Introduction Basal insulin (BI) plays an important role in treating type 2 diabetes (T2D), especially when oral antidiabetic (OAD) medications are insufficient for glycemic control. We conducted a retrospective, observational study using electronic m
Publikováno v:
International Journal of Angiology. 5:149-156
Sporadic reports allude to the similarities between the subcutaneous and fascial sclerosis of venous disease and lymphedema with that of eosinophilic fasciitis and the related fasciitis-panniculitis syndrome. The objective of the present study was to